• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Antipsychotics for Methamphetamine Psychosis
RESEARCH UPDATE

Antipsychotics for Methamphetamine Psychosis

January 18, 2022
Sanya Virani, MD.
From The Carlat Addiction Treatment Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Sanya Virani, MD. Dr. Virani has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Srisurapanont M et al, Drug Alcohol Depend 2021;219:108467

STUDY TYPE: Systematic review and network meta-analysis

Methamphetamine psychosis (MAP) is difficult to treat, and there are only so many antipsychotics in our repertoire. Randomized clinical trials (RCTs) to manage MAP are few and far between, and the literature thus far has indicated that no antipsychotic is superior to any other. What is a clinician to do?

In this study, the authors conducted a network meta-analysis of six RCTs with a total of 395 participants. Effectively, they created a head-to-head comparison of six antipsychotics for MAP [risperidone (four trials, n = 129); haloperidol (three trials, n = 93); aripiprazole (two trials, n = 48); paliperidone extended release (ER), quetiapine, and olanzapine (one trial each for a total n = 125)] and examined each medication for their ability to reduce psychotic symptoms.

The evidence in each trial was judged to be of low or very low quality, and none of the trials individually found significant differences between medications. However, when data from all the trials were pooled, the authors were able to establish somewhat of a hierarchy. Comparisons between medications were reported as standardized mean difference, which is a way of standardizing outcomes across studies that measure similar outcomes in various ways. Of all the possible head-to-head medication comparisons, a few significant differences were found. Quetiapine (300 mg/day) and olanzapine (20 mg/day) were the major winners and were superior to risperidone (4–8 mg/day) and aripiprazole (15 mg/day) for psychotic symptoms. Aripiprazole was the big loser—it was inferior to haloperidol (6–20 mg/day) and paliperidone ER (9 mg/day), as well as quetiapine and olanzapine.

The authors acknowledge that only six RCTs met inclusion criteria, and that the total n did not allow for robust conclusions to be drawn in all drug comparisons. Other shortcomings included lack of placebo control and overall study heterogeneity. The authors also point out that the D2 receptor blockade caused by these medications in the setting of methamphetamine withdrawal could heighten anhedonia and theoretically increase risk of return to drug use. Hyperphagia and hypersomnia resulting from methamphetamine withdrawal might compound the side effects from olanzapine and quetiapine. Given that MAP is often self-limiting, the recommendation is to taper off the antipsychotic after resolution of psychotic symptoms, typically a maximum of four weeks after methamphetamine use.

CATR’S Take
We recommend considering quetiapine and olanzapine first when treating patients for MAP, and reserving aripiprazole as a third-line treatment only. Be aware of side effect burden and taper these medications off as soon as possible.
Addiction Treatment Research Update
KEYWORDS antipsychotic meta-analysis methamphetamines psychosis
    Sanya Virani, MD.

    Add-On Buprenorphine for Methamphetamine Use Disorder

    More from this author
    www.thecarlatreport.com
    Issue Date: January 18, 2022
    SUBSCRIBE NOW
    Table Of Contents
    A Primer on Vaping: 15 Years On
    Using Smoking Cessation Medications in Patients With Mental Illness
    Antipsychotics for Methamphetamine Psychosis
    Meds for Alcohol Use Disorders
    CME Post-Test - Smoking Cessation, CATR, January/February 2022
    DOWNLOAD NOW
    Featured Book
    • OUDFB1e_Cover_Binding.png

      Treating Opioid Use Disorder—A Fact Book (2024)

      All the tools you need to assess and treat patients struggling with opioid use disorder. 
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.